Dr. Douglas Stewart reviews medical content for Healthwise, a nonprofit organization with a mission to help people make better health decisions. Dr. Stewart is a professor in the departments of Medicine and Oncology, Divisions of Medical Oncology, Hematology, and Hematological Malignancies, at the University of Calgary in Alberta. He is also a medical oncologist in the Department of Medicine at the Tom Baker Cancer Centre and The Calgary Health Region.

Board Certifications

Specialist Certificate in Medical Oncology

FRCPC Internal Medicine

Healthwise Knowledgebase Topics Reviewed

Non-Hodgkin's Lymphoma

Breast Cancer

Breast Cancer, Metastatic or Recurrent

Lymphedema

Inflammatory Breast Cancer

Education

MD: With Distinction, University of Alberta, Edmonton, AB, 1987

FRCPC: Internal Medicine, Medical Oncology Certification, University of Ottawa, Ottawa, ON, 1993

Fellowship: Bone Marrow Transplantation and Lymphoma, University of Nebraska, Omaha, NE, 1994

Academic Appointments

Professor, Departments of Oncology and Medicine, University of Calgary

Hospital Affiliations

Tom Baker Cancer Centre

The Calgary Health Region

Professional Affiliations

Royal College of Physicians and Surgeons of Canada

Canadian Medical Protective Association

Canadian Association of Medical Oncologists

Canadian Hematology Society

American Society of Clinical Oncology

European Bone Marrow Transplant Registry

American Society of Hematology

Selected Publications

1. Russell J, Savoie M L, Balogh A, Turner A R, Larratt L, Chaudhry M A, Storek J, Bahlis N, Brown C, Quinlan D, Geddes M, Stewart D (2007) Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total body irradiation, and thymoglobulin. Biology of Blood and Marrow Transplantation, 13(7): 814–821.
2. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, Jones A, Brown C, Russell JA (2006). Upfront double high dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor prognosis aggressive non-Hodgkin’s lymphoma. Blood, 107(12): 4623–4627.
3. Stewart DA, Paterson AHG, Ruether JD, Russell J, Craighead P, Smylie M, Mackey J (2005). High dose mitoxantrone-vinblastine-Cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: Final results of a prospective, multicentre study. Annals of Oncology, 16(9): 1463–1468.
4. Conner-Spady BL, Cumming C, Nabholtz J-M, Jacobs P, Stewart D (2005). A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplantation, 36(3): 251–259.
5. Thirukkumaran CM, Luider JM, Stewart, DA, Cheng T, Lupichuk SM, Nodwell MJ, Russell JA, Auer IA, Morris DM (2003). Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood, 102(1): 377–387.

Financial Disclosure

Dr. Stewart has received grants from the Alberta Cancer Foundation, Hoffmann-La Roche, National Cancer Institute of Canada, Health Canada Best Practices Contribution Program, Calgary Laboratory Services, and GlaxoSmithKline.